Genetic polymorphism of γ-glutamyl hydrolase in chinese acute leukemia children and identification of a novel double nonsynonymous mutation

Pediatric Hematology and Oncology

Volumn 29, Issue 4, 2012, Pages 303-312

  Chen, Xiaowen ^a   Wen, Feiqiu ^a   Yue, Lijie ^a   Li, Changgang ^a  

^a SHENZHEN CHILDREN'S HOSPITAL   (China)

Author keywords

glutamyl hydrolase; Acute leukemia; Children; Mutation; Polymorphism

Indexed keywords

COMPLEMENTARY DNA; GAMMA GLUTAMYL HYDROLASE; METHOTREXATE; MUTANT PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; AFRICAN AMERICAN; ALLELE; ANEMIA; ARTICLE; BASE PAIRING; CANCER CHEMOTHERAPY; CANCER PATIENT; CAUCASIAN; CHILD; CHINESE; CONTROLLED STUDY; DENATURING GRADIENT GEL ELECTROPHORESIS; DNA SEQUENCE; DRUG MEGADOSE; ENZYME ACTIVITY; ENZYME ANALYSIS; GENE EXPRESSION; GENE FREQUENCY; GENE MUTATION; GENETIC ANALYSIS; GENETIC CODE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HETEROZYGOTE; HUMAN; HUMAN TISSUE; INFANT; JAPANESE; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MOLECULAR CLONING; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; NEWBORN; PRESCHOOL CHILD; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; THROMBOCYTOPENIA;

ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; CHILD; CHILD, PRESCHOOL; CHINA; CLONING, MOLECULAR; DNA, COMPLEMENTARY; FEMALE; GAMMA-GLUTAMYL HYDROLASE; GENE FREQUENCY; HUMANS; INFANT; INFANT, NEWBORN; LEUKEMIA, MYELOID, ACUTE; MALE; POINT MUTATION; POLYMORPHISM, GENETIC; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 84860851101     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.3109/08880018.2012.657767     Document Type: Article

References (19)

1. Galivan J, Ryan TJ, Chave K, et al. Glutamyl hydrolase: pharmacological role and enzymatic characterization. Pharmacol Ther. 2000;85:207-215.
2. Galivan J, Ryan T, Rhee M, et al. Glutamyl hydrolase: properties and pharmacologic impact. Semin Oncol. 1999;26:33-37.
3. Koizumi S, Curt GA, Fine RL, et al. Formation of methotrexate polyglutamates in purified myeloid precursor cells from normal human bonemarrow. J Clin Invest. 1985;75:1008-1014.
4. Rhee MS, Wang Y, Nair MG, Galivan J. Acquisition of resistance to antifolates caused by enhanced gamma-glutamyl hydrolase activity. Cancer Res. 1993;53:2227-2230.
5. Yao R, Rhee MS,Galivan J. Effects of gamma-glutamyl hydrolase on folyl and antifolylpolyglutamates in cultured H35 hepatoma cells. Mol Pharmacol. 1995;48:505-511.
6. Rumberger BG, Schmid FA, Otter GM, Sirotnak FM. Preferential selection during therapy in vivo by edatrexate compared to methotrexate of resistant L1210 cell variants with decreased folylpolyglutamate synthetase activity. Cancer Commun. 1990;2:305-310.
7. McCloskey DE, McGuire JJ, Russell CA, et al. Decreased folylpolyglutamate synthetase activity as a mechanism of methotrexate resistance in CCRF-CEM human leukemia sublines. J Biol Chem. 1991;266:6181-6187.
8. PizzornoG,MorosonBA,CashmoreAR, et al.Multifactorial resistance to 5,10-dideazatetrahydrofolic acid in cell lines derived from human lymphoblastic leukemia CCRF-CEM. Cancer Res. 1995;55:566-573.
9. Longo GS, Gorlick R, Tong WP, et al. gamma-Glutamyl hydrolase and folylpolyglutamate synthetase activities predict polyglutamylation of methotrexate in acute leukemias. Oncol Res. 1997;9:259-263.
10. Cheng Q, Wu B, Kager L, et al. A substrate specific functional polymorphism of human gammaglutamyl hydrolase alters catalytic activity and methotrexate polyglutamate accumulation in acute lymphoblastic leukaemia cells. Pharmacogenetics. 2004;14:557-567.
11. Hayashi H, Fujimaki C, Inoue K, et al. Genetic polymorphism of C452T (T127I) in human gammaglutamyl hydrolase in a Japanese population. Biol Pharm Bull. 2007;30:839-841.
12. Chen X, Yue L, Li C, Li C. A novel G473Amutation in the glucose-6-phosphate dehydrogenase gene. Pediatr Blood Cancer. 2010;55:383-385.
13. Luo XQ, Ke ZY, Guan XQ, et al.Thecomparison of outcome and cost of three protocols for childhood non-high risk acute lymphoblastic leukemia in China. Pediatr Blood Cancer. 2008; 51:204-209.
14. Chave KJ, Auger IE,Galivan J, Ryan TJ.Molecularmodeling and site-directedmutagenesis define the catalyticmotif in human gamma-glutamyl hydrolase. J Biol Chem. 2000;275:40365-40370.
15. Panetta JC, Wall A, Pui CH, et al. Methotrexate intracellular disposition in acute lymphoblastic leukemia: a mathematical model of gamma-glutamyl hydrolase activity. Clin Cancer Res. 2002;8:2423-2429.
16. Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncologist. 2006;11:694-703.
17. HayashiH, Fujimaki C,Daimon T, et al.Genetic polymorphisms in folate pathway enzymes as a possiblemarker for predicting the outcome ofmethotrexate therapy in Japanese patients with rheumatoid arthritis. J Clin Pharmacol Ther. 2009;34:355-361.
18. Guldberg P, Guttler F. A simple method for identification of point mutations using denaturing gradient gel electrophoresis. Nucleic Acids Res. 1993;21:2261-2262.
19. van der Hout AH, van den Ouweland AM, van der Luijt RB, et al. A DGGE system for comprehensive mutation screening of BRCA1 and BRCA2: application in a Dutch cancer clinic setting. Hum Mutat. 2006;27:654-666.